Anti-cancer effects of Tranilast: An update
<p dir="ltr">Tranilast (TRN) or (N-3,4 -dimethoxy cinnamoyl]-anthranilic acid) is an analog of a tryptophan metabolite and is identified mainly as an anti-allergic agent with limited side effects. The anti-cancer effects of tranilast either alone or in combination with chemotherapeut...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , |
| منشور في: |
2021
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513546423894016 |
|---|---|
| author | Soha Osman (17280655) |
| author2 | Afsheen Raza (492657) Lobna Al-Zaidan (14557394) Varghese Philipose Inchakalody (14153292) Maysaloun Merhi (4246147) Kirti S. Prabhu (4246144) Nouha Abdelaziz (17280658) Shereena Hydrose (14442135) Shahab Uddin (154400) Said Dermime (79420) |
| author2_role | author author author author author author author author author |
| author_facet | Soha Osman (17280655) Afsheen Raza (492657) Lobna Al-Zaidan (14557394) Varghese Philipose Inchakalody (14153292) Maysaloun Merhi (4246147) Kirti S. Prabhu (4246144) Nouha Abdelaziz (17280658) Shereena Hydrose (14442135) Shahab Uddin (154400) Said Dermime (79420) |
| author_role | author |
| dc.creator.none.fl_str_mv | Soha Osman (17280655) Afsheen Raza (492657) Lobna Al-Zaidan (14557394) Varghese Philipose Inchakalody (14153292) Maysaloun Merhi (4246147) Kirti S. Prabhu (4246144) Nouha Abdelaziz (17280658) Shereena Hydrose (14442135) Shahab Uddin (154400) Said Dermime (79420) |
| dc.date.none.fl_str_mv | 2021-09-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.biopha.2021.111844 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Anti-cancer_effects_of_Tranilast_An_update/24433225 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Tranilast Anti-carcinogenic drug Anti-inflammatory drug Combination therapy |
| dc.title.none.fl_str_mv | Anti-cancer effects of Tranilast: An update |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Tranilast (TRN) or (N-3,4 -dimethoxy cinnamoyl]-anthranilic acid) is an analog of a tryptophan metabolite and is identified mainly as an anti-allergic agent with limited side effects. The anti-cancer effects of tranilast either alone or in combination with chemotherapeutic drugs have been evidenced in several pre-clinical studies. The main mechanism of action of tranilast includes targeting and modulation of various signaling and immune regulatory pathways including Transforming growth factor-beta (TGF-β), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), phosphatidylinositol 3-kinase (PI3K), MAP-Kinase (MAPK), Protein kinase B (Akt/PKB), c-Jun N-terminal kinase, modulation of cancer stem cells, etc. Most of these pathways are involved in tumor proliferation, invasion, and metastasis and it is postulated that tranilast, with its low toxicity profile and high anti-carcinogenic abilities, can serve as a potential anti-tumorigenic agent. The main aim of this review is to provide updated information on the anti-cancer effects of tranilast and its significance as a therapeutic agent.</p><h2>Other Information</h2><p dir="ltr">Published in: Biomedicine & Pharmacotherapy<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.biopha.2021.111844" target="_blank">https://dx.doi.org/10.1016/j.biopha.2021.111844</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_235f89a751efe524f4293917b815bd2e |
| identifier_str_mv | 10.1016/j.biopha.2021.111844 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/24433225 |
| publishDate | 2021 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Anti-cancer effects of Tranilast: An updateSoha Osman (17280655)Afsheen Raza (492657)Lobna Al-Zaidan (14557394)Varghese Philipose Inchakalody (14153292)Maysaloun Merhi (4246147)Kirti S. Prabhu (4246144)Nouha Abdelaziz (17280658)Shereena Hydrose (14442135)Shahab Uddin (154400)Said Dermime (79420)Biomedical and clinical sciencesOncology and carcinogenesisPharmacology and pharmaceutical sciencesTranilastAnti-carcinogenic drugAnti-inflammatory drugCombination therapy<p dir="ltr">Tranilast (TRN) or (N-3,4 -dimethoxy cinnamoyl]-anthranilic acid) is an analog of a tryptophan metabolite and is identified mainly as an anti-allergic agent with limited side effects. The anti-cancer effects of tranilast either alone or in combination with chemotherapeutic drugs have been evidenced in several pre-clinical studies. The main mechanism of action of tranilast includes targeting and modulation of various signaling and immune regulatory pathways including Transforming growth factor-beta (TGF-β), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), phosphatidylinositol 3-kinase (PI3K), MAP-Kinase (MAPK), Protein kinase B (Akt/PKB), c-Jun N-terminal kinase, modulation of cancer stem cells, etc. Most of these pathways are involved in tumor proliferation, invasion, and metastasis and it is postulated that tranilast, with its low toxicity profile and high anti-carcinogenic abilities, can serve as a potential anti-tumorigenic agent. The main aim of this review is to provide updated information on the anti-cancer effects of tranilast and its significance as a therapeutic agent.</p><h2>Other Information</h2><p dir="ltr">Published in: Biomedicine & Pharmacotherapy<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.biopha.2021.111844" target="_blank">https://dx.doi.org/10.1016/j.biopha.2021.111844</a></p>2021-09-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.biopha.2021.111844https://figshare.com/articles/journal_contribution/Anti-cancer_effects_of_Tranilast_An_update/24433225CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/244332252021-09-01T00:00:00Z |
| spellingShingle | Anti-cancer effects of Tranilast: An update Soha Osman (17280655) Biomedical and clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Tranilast Anti-carcinogenic drug Anti-inflammatory drug Combination therapy |
| status_str | publishedVersion |
| title | Anti-cancer effects of Tranilast: An update |
| title_full | Anti-cancer effects of Tranilast: An update |
| title_fullStr | Anti-cancer effects of Tranilast: An update |
| title_full_unstemmed | Anti-cancer effects of Tranilast: An update |
| title_short | Anti-cancer effects of Tranilast: An update |
| title_sort | Anti-cancer effects of Tranilast: An update |
| topic | Biomedical and clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Tranilast Anti-carcinogenic drug Anti-inflammatory drug Combination therapy |